Updates in the Management of Stage III Non-Small Cell Lung Cancer (NSCLC) - Episode 7

Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC

, , ,

The panel discusses the factors that go into selecting patients for adjuvant therapy.

EP. 1: Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%
EP. 2: Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC
EP. 3: Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC
EP. 4: Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC
EP. 5: Management of Borderline Resectable NSCLC
EP. 6: Management of Resectable Early Stage NSCLC with Actionable Mutations
Now Viewing
EP. 7: Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC
EP. 8: Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease
EP. 9: Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC
EP. 10: Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

Video content above is prompted by the following:

How do you select patients with potentially resectable stage III NSCLC for adjuvant therapy?

How does your approach differ based on PD-L1 status? Presence of EGFR/ALK alterations?